Vertex Pharmaceuticals Waits to Hit the Triple [The Motley Fool]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: The Motley Fool
The biotech's current cystic fibrosis drugs are still growing well. Vertex Pharmaceuticals ( NASDAQ:VRTX ) continues to post substantial revenue growth, although many investors are rightfully looking ahead to its next-generation triple combinations for cystic fibrosis. Vertex Pharmaceuticals results: The raw numbers Metric Q3 2018 Q3 2017 Year-Over-Year Change Revenue $784.5 million $578.2 million 35% Income from operations $205.6 million ($326.0 million) N/A EPS $0.50 ($0.41) N/A Adjusted EPS $1.09 $0.53 106% Data source: Vertex Pharmaceuticals. EPS = earnings per share. What happened with Vertex Pharmaceuticals this quarter? Combined sales of Vertex's cystic fibrosis drugs -- Kalydeco, Orkambi, and Symdeko -- were up 42% year over year. Overall revenue didn't grow quite as fast because royalty revenue was down year over year, as was coll
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Global Vaccine Contract Manufacturing Market Trends Analysis Report 2024-2030: Capacity Expansion by Contract Manufacturers, & Vaccination Innovation and Robust Vaccine Pipeline Bolsters Growth [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis [Seeking Alpha]Seeking Alpha
- U.S. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030: Robust Pipeline and Growing Prevalence of Target Diseases Fueling Growth and Developments [Yahoo! Finance]Yahoo! Finance
- VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETESPR Web
- VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/5/24 - Beat
VRTX
Sec Filings
- 4/17/24 - Form 4
- 4/16/24 - Form PX14A6G
- 4/11/24 - Form SC
- VRTX's page on the SEC website